AtaiBeckley Redomiciles to U.S., Aligning Pharma Strategy
New York | December 30, 2025 — AtaiBeckley Inc., a clinical-stage biopharmaceutical company focused on developing rapid-acting and scalable...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
New York | December 30, 2025 — AtaiBeckley Inc., a clinical-stage biopharmaceutical company focused on developing rapid-acting and scalable...
Vancouver, British Columbia — November 20, 2025 — PreveCeutical Medical Inc. has issued a formal clarification regarding its earlier...
